Gilead Sciences' Kite unit has showcased three new CAR-T therapies at ASH, headed by multiple myeloma candidate ...

The company's BCMAxCD3 bispecific antibody Lynozyfic (linvoseltamab) got its first FDA approval as a fifth-line or later ...

This approach offers an enhanced therapeutic effect with minimal systemic toxicity, addressing one of oncology’s ...

Social determinants of health (SDOH) encompass a wide range of non-medical factors that influence health and well-being.

In line with its deregulatory stance under new Commissioner Marty Makary, the US regulator has launched TEMPO – ...

And Simon Kohl, founder and CEO of Latent Labs, knows this intimately. In a new episode of the pharmaphorum podcast, Kohl ...

At this year's ASH congress, the results of the phase 1b/2 DURGA-1 of AZD0120 – a dual BCMA and CD19-directed CAR-T therapy – ...

Bayer has started a phase 2a trial of an antibody that it hopes could provide a targeted, potentially disease-modifying ...

The FDA has now started a review of the highly anticipated drug, and AZ is using a priority review voucher to shorten the ...

CD19-targeted therapy Breyanzi (lisocabtagene maraleucel) can now be used to treat adults with MZL – a rare and form of ...

Eli Lilly's fast-growing blood cancer drug Jaypirca has bagged a new FDA approval as an earlier treatment for relapsed or ...

Bayer has started a phase 3 trial of its intrauterine contraceptive Mirena in an endometrial condition that can lead to ...